Figure 2.Figure 2
Kaplan-Meier curve for time to first TESAE of infections and infestations in RTX-exposed vs RTX-Naïve patients. Kaplan-Meier estimates were calculated to evaluate the time to first TESAE of infections and infestations in patients treated with ravulizumab, stratified by prior RTX exposure. Patients who did not experience a TESAE of infections and infestations were censored at the earliest date of study completion, discontinuation date, last assessment date, death date, and data cutoff date. RTX, rituximab; TESAE, treatment-emergent serious adverse event.